Indian Scenario on Breast Cancer

Breast Cancer is the most common cancer in women in India. 27.7% of all new cancers detected in women in India in the year 2018, were breast cancers.

One woman is diagnosed with
breast cancer, in India, every 4
minutes

*One woman dies of Breast
cancer, in India, every 8
minutes

Current Challenges in Breast Cancer Diagnosis

HER2

PR

ER

ER/PR/HER2 only provide a superficial protein-based view of a tumor and not the underlying biology driivng its growth

Clinical factors onlye provide part of the story

Genomic information is typically not available in time for initial pre-operative consultation.

What is BluePrint Molecular Subtyping

BluePrint, the 80-gene molecular subtyping assay, goes beyond the cell surface to evaluate the underlying biology of a tumor and what is driving its growth.

Recommendations

ASCO recommends MamaPrint as the only test of its kind recommended to inform treatment decision for both lymph-node positive and lymph node negative breast cancer patients

Test Details

Test Code Test Name Technique Speciment Tat / Reported on
SMO10242 MammaPrint+BluePrint Combination MammaPrint+
BluePrint Combination
Molecular Array Specimen - Formalin-fixed paraffin-embedded tissue block or 10 unstained slides with a 5 micron section on each slide. Must contain at least 30% invasive tumor. 18th Working Day
SMO10364 MammaPrint Assay Molecular Array 10 unstained slides with a 5 micron section on each slide. Must contain at least 30% invasive tumor. 18th Working Day